Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

In Brief: Tagamet HB 200

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Tagamet HB 200: Jordan, McGrath, Case & Taylor, New York City, is new ad agency for SmithKline Beecham's H2 antagonist. Ogilvy & Mather previously had the estimated $20 mil.-$25 mil. account. JMC&T already handles advertising for SB's Tums, Gaviscon, Nicoderm CQ and Nicorette brands. The change follows an internal restructuring of SB's gastrointestinal category management, after which the company opted to unify its G-I product ads in one company. O&M just received an undisclosed product account from SmithKline, in addition to handling worldwide advertising for the company's Panadol brand of acetaminophen. New York City-based Grey Advertising also has SB accounts, among them Aquafresh...

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Cancer Trials: FDA Wants Lower Performance Status Eligibility But Primary Analysis Exclusion OK

US FDA's Califf Defends Agency Work On Marijuana Rescheduling, Animal Testing

Overall Survival Is Not A Required Primary Endpoint In All Cancer Trials, US FDA Says

Australia Calls For Companion Testing Plans For Drugs Requiring A CDx

See All
UsernamePublicRestriction

Register

PS087609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By